Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction

Crinetics Pharmaceuticals, Inc.

Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.
Atumelnant 80mg in CAH cohort 4: 67% mean reduction in androstenedione, 88% of patients achieved physiologic glucocorticoid doses.
No serious adverse events or hepatic transaminase AEs in cohort 4 or open-label extension (25 patients, >750 weeks cumulative exposure).
About half of new PALSONIFY bottles reimbursed without Quickstart bridge; 12-month prior authorizations typical.
Crinetics hosts investor call today 8:30 AM ET to discuss results and outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.